» Articles » PMID: 21159923

Antibody Response to Polyhistidine-tagged Peptide and Protein Antigens Attached to Liposomes Via Lipid-linked Nitrilotriacetic Acid in Mice

Overview
Date 2010 Dec 17
PMID 21159923
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Particulate delivery systems enhance antibody responses to subunit antigens. However, covalent attachment of protein antigens can disrupt protein structure and mask critical epitopes, altering the antibody response to the antigen. In this report, we evaluate noncovalent metal chelation via nitrilotriacetic acid (NTA) as a nondestructive method to attach peptide and protein antigens to liposomes. Two model antigens, ovalbumin (OVA) and a peptide derived from the membrane-proximal region of HIV-1 gp41 (N-MPR), were polyhistidinylated and attached to liposomes via monovalent NTA (mono-NTA; K(D) [equilibrium dissociation constant], ∼10 μM), trivalent NTA (tris-NTA; K(D), ∼1 nM), or a covalent linkage. Attachment of N-MPR, but not OVA, to liposomes via an NTA lipid elicited stronger antibody responses in BALB/c mice than a formulation in which unassociated antigen was simply admixed with control liposomes lacking NTA. However, the tris-NTA linkage did not increase antibody responses to either N-MPR or OVA compared to the level for the mono-NTA linkage, despite the greater liposomal association of the antigen. For both antigens, covalently attaching them to a lipid elicited significantly stronger antibody responses than NTA-anchored antigens (OVA titer, 3.4 × 10(6) versus 1.4 × 10(6) to 1.6 × 10(6) [P < 0.001]; N-MPR titer, 4.4 × 10(4) versus 5.5 × 10(2) to 7.6 × 10(2) [P < 0.003]). The data indicate that NTA linkages may increase antibody titers to weak antigens such as N-MPR, but NTA-mediated attachment remains inferior to covalent conjugation. Moreover, enhancements in antigen-liposome affinity do not result in increased antibody titers. Thus, additional improvements of NTA-mediated conjugation technology are necessary to achieve an effective, nondestructive method for increasing the humoral response to antigens in particulate vaccines.

Citing Articles

A modular protocol for virosome display of subunit vaccine antigens.

Rosado V, Adams L, Yousif A, Sangesland M, Ronsard L, Okonkwo V STAR Protoc. 2025; 6(1):103610.

PMID: 39891914 PMC: 11834092. DOI: 10.1016/j.xpro.2025.103610.


Advances in Receptor-Mediated, Tumor-Targeted Drug Delivery.

Large D, Soucy J, Hebert J, Auguste D Adv Ther (Weinh). 2024; 2(1).

PMID: 38699509 PMC: 11064891. DOI: 10.1002/adtp.201800091.


Human cell-expressed tag-free rhMFG-E8 as an effective radiation mitigator.

Chaung W, Ma G, Jacob A, Brenner M, Wang P Sci Rep. 2023; 13(1):22186.

PMID: 38092894 PMC: 10719321. DOI: 10.1038/s41598-023-49499-y.


Viral nanoparticle vaccines against S100A9 reduce lung tumor seeding and metastasis.

Chung Y, Ortega-Rivera O, Volckaert B, Jung E, Zhao Z, Steinmetz N Proc Natl Acad Sci U S A. 2023; 120(43):e2221859120.

PMID: 37844250 PMC: 10614828. DOI: 10.1073/pnas.2221859120.


Optimization of an alum-anchored clinical HIV vaccine candidate.

Rodrigues K, Cottrell C, Steichen J, Groschel B, Abraham W, Suh H NPJ Vaccines. 2023; 8(1):117.

PMID: 37573422 PMC: 10423202. DOI: 10.1038/s41541-023-00711-0.


References
1.
Kazzaz J, Neidleman J, Singh M, Ott G, OHagan D . Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J Control Release. 2000; 67(2-3):347-56. DOI: 10.1016/s0168-3659(00)00226-1. View

2.
Rouillard J, Lee W, Truan G, Gao X, Zhou X, Gulari E . Gene2Oligo: oligonucleotide design for in vitro gene synthesis. Nucleic Acids Res. 2004; 32(Web Server issue):W176-80. PMC: 441539. DOI: 10.1093/nar/gkh401. View

3.
Van Broekhoven C, Altin J . A novel system for convenient detection of low-affinity receptor-ligand interactions: chelator-lipid liposomes engrafted with recombinant CD4 bind to cells expressing MHC class II. Immunol Cell Biol. 2001; 79(3):274-84. DOI: 10.1046/j.1440-1711.2001.01010.x. View

4.
Koff R . Immunogenicity of hepatitis B vaccines: implications of immune memory. Vaccine. 2002; 20(31-32):3695-701. DOI: 10.1016/s0264-410x(02)00405-x. View

5.
Cooper H, Jemmerson R, Hunt D, Griffin P, Yates 3rd J, Shabanowitz J . Site-directed chemical modification of horse cytochrome c results in changes in antigenicity due to local and long-range conformational perturbations. J Biol Chem. 1987; 262(24):11591-7. View